Literature DB >> 2150592

Pharmacology and therapeutic effects of nicorandil.

M Kinoshita1, K Sakai.   

Abstract

Nicorandil, a nicotinamide derivative, is an orally efficacious antianginal drug possessing a nitrate moiety in its chemical structure. This drug is an effective and well-tolerated treatment for various types of angina pectoris. Its general efficacy is similar to that of nitrates, with several unique effects on the cardiovascular system. Nicorandil causes sustained dilation of both the arterial resistance and conductive vessels, thus markedly dilating the coronary artery and increasing coronary blood flow. In addition, nicorandil, unlike nitroglycerin or isosorbide dinitrate, possesses little hemodynamic effect on heart rate, blood pressure, or cardiac contractility with clinical doses yielding antianginal effects. The mechanism causing coronary vasodilation has not been completely clarified but appears to be associated partly with increases in c-GMP, as well as the hyperpolarization of the smooth muscle membrane. Nicorandil, in single oral doses of 10-30 mg, has been shown to be effective in chronic stable angina, as assessed objectively by increases in exercise duration and/or the time to onset of ST-segment depression during treadmill exercise. In open studies and controlled efficacy evaluations, nicorandil in daily oral doses of 15-40 mg demonstrated significant effectiveness in the treatment of various types of angina pectoris. Headaches due to vasodilation may occur, and some side effects occurred in 5.1-34% of patients receiving nicorandil, but were generally minor in nature. There was no depressant effect on atrioventricular conduction, which occurs frequently in patients treated with calcium antagonists of the verapamil and diltiazem type. Nicorandil may be effective even in patients with rest and effort angina who do not respond to combination therapy with calcium antagonists and oral nitrates. Thus, nicorandil appears to be a valuable addition to the arsenal of antianginal drugs due to its low incidence of serious side effects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150592     DOI: 10.1007/bf01856503

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  85 in total

1.  Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.

Authors:  W R Kukovetz; S Holzmann
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs.

Authors:  T Endo; J Nejima; K Kiuchi; S Fujita; K Kikuchi; H Hayakawa; H Okumura
Journal:  J Cardiovasc Pharmacol       Date:  1988       Impact factor: 3.105

3.  Effects of nicorandil on large epicardial coronary artery in conscious dogs.

Authors:  A Yamada; H Tomoike; Y Hayashi; H Nishijima; M Nakamura
Journal:  Arzneimittelforschung       Date:  1987-11

4.  Nicorandil-induced changes in the distribution of cardiac output and coronary blood flow in pigs.

Authors:  P D Verdouw; L M Sassen; D J Duncker; I O Schmeets; R J Rensen; P R Saxena
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-09       Impact factor: 3.000

5.  Atrioventricular dissociation and sinus arrest induced by oral diltiazem.

Authors:  T Ishikawa; T Imamura; Y Koiwaya; K Tanaka
Journal:  N Engl J Med       Date:  1983-11-03       Impact factor: 91.245

6.  Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure.

Authors:  U Elkayam; D Kulick; N McIntosh; A Roth; W Hsueh; S H Rahimtoola
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

7.  Nicorandil releases acetylcholine-induced sustained coronary arterial constriction in monkeys and baboons.

Authors:  K Satoh; M Maruyama; S Yamashita; N Taira
Journal:  Jpn Heart J       Date:  1984-03

8.  Effects of nicorandil and verapamil, antianginal agents, on plasma digoxin concentrations in rats and dogs.

Authors:  Y Hinohara; T Yamazaki; O Kuromaru; N Homma; K Sakai
Journal:  J Pharm Pharmacol       Date:  1987-07       Impact factor: 3.765

9.  Effects of 2-nicotinamidethyl nitrate (SG-75), a new antianginal drug, on the cyclic AMP phosphodiesterase activity.

Authors:  M Endoh; T Yanagisawa; N Taira
Journal:  Tohoku J Exp Med       Date:  1980-02       Impact factor: 1.848

10.  Effects of 2-nicotinamidoethyl nitrate on smooth muscle cells of the guinea-pig mesenteric and portal veins.

Authors:  T Karashima; T Itoh; H Kuriyama
Journal:  J Pharmacol Exp Ther       Date:  1982-05       Impact factor: 4.030

View more
  14 in total

Review 1.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

2.  [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].

Authors:  C Bickel; H J Rupprecht; A Tyrtania; J Rörig; J Meyer
Journal:  Med Klin (Munich)       Date:  1999-02-15

3.  Double-blind comparison of the acute effects of two relevant doses of oral nicorandil on central hemodynamics, left ventricular function, and myocardial contractility.

Authors:  A Baumbach; U Braun; G Döring; K K Haase; W Voelker; K R Karsch
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

4.  Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms.

Authors:  H Yamabe; H Namura; T Yano; H Fujita; S Kim; M Iwahashi; K Maeda; M Yokoyama
Journal:  Cardiovasc Drugs Ther       Date:  1995-12       Impact factor: 3.727

Review 5.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

6.  The haemodynamic effects and pharmacokinetics of intravenous nicorandil in healthy volunteers.

Authors:  D L Wolf; J J Ferry; A E Hearron; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

7.  Acute and subacute effects of nicorandil and isosorbide dinitrate on vessel wall properties of large arteries and hemodynamics in healthy volunteers.

Authors:  M J Kool; J J Spek; H A Struyker Boudier; A P Hoeks; R S Reneman; R H van Herwaarden; L M Van Bortel
Journal:  Cardiovasc Drugs Ther       Date:  1995-04       Impact factor: 3.727

8.  The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers.

Authors:  D L Wolf; A E Hearron; C M Metzler; J J Ferry; M O Froeschke; J R Luderer
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Nicorandil improves myocardial function by regulating plasma nitric oxide and endothelin-1 in coronary slow flow.

Authors:  Zuoyuan Chen; Xiuhua Chen; Shan Li; Xuezhen Huo; Xiuxiu Fu; Xiaonan Dong
Journal:  Coron Artery Dis       Date:  2015-03       Impact factor: 1.439

10.  Vasodilator effect of nicorandil on retinal blood vessels in rats.

Authors:  Naoto Ogawa; Maki Saito; Asami Mori; Kenji Sakamoto; Sokichi Kametaka; Tsutomu Nakahara; Kunio Ishii
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-05-25       Impact factor: 3.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.